版本:
中国

BRIEF-Bristol-Myers says Opdivo in combination with Yervoy and Opdivo Monotherapy significantly improved overall survival

April 3 Bristol-myers Squibb Co

* Opdivo (nivolumab) in combination with Yervoy (ipilimumab) and Opdivo Monotherapy significantly improved overall survival versus Yervoy alone in patients with previously untreated advanced melanoma

* Bristol-Myers Squibb Co - first overall survival (os) data from phase 3 checkmate -067 clinical trial

* Bristol-Myers Squibb Co says with a minimum follow-up of 28 months, median os had not yet been reached in either of two Opdivo treatment groups

* Bristol-Myers Squibb Co - updated safety data reported in new analysis were consistent with previously reported experience

* Bristol-Myers Squibb Co - safety profile is consistent with previous studies, with no cumulative toxicity with combination therapy or new safety signals

* Bristol-Myers Squibb Co - two-year os rates were 64% for Opdivo plus Yervoy combination, 59% for Opdivo alone and 45% for Yervoy alone Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐